EUVIMEDEUVIMED entdecken
LeserbriefFallbericht

Efficacy of canakinumab for mosaic tumor necrosis factor receptor associated periodic syndrome

Alexandre Terré, Mathieu Vautier, Jean-Emmanuel Kahn, Sophie Georgin-Lavialle, Guilaine Boursier

European Journal of Internal Medicine · 2024

DOI: 10.1016/j.ejim.2024.01.034 ↗

Kurz gefasst

Leserbrief in der Zeitschrift European Journal of Internal Medicine, 2024. Verfasst von Alexandre Terré und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Sorbonne University, AP-HP, Tenon hospital, Centre de référence des maladies auto-inflammatoires et des amyloses d'o…. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 9 Literaturangaben. Gefördert von: Institut Imagine Institut des Maladies Génétiques.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedFemaleHumansMaleAntibodies, MonoclonalFeverHereditary Autoinflammatory DiseasesReceptors, Tumor Necrosis Factor, Type ITreatment OutcomeAdultMiddle Aged

Stichwörter der Autor:innen

CanakinumabMosaicSomatic mutationTNFRSF1ATRAPS syndrome

Substanzen

Antibodies, MonoclonalAntibodies, Monoclonal, HumanizedcanakinumabReceptors, Tumor Necrosis Factor, Type I

Autor:innen und Institutionen

  • Department of Internal Medicine, Sorbonne University, AP-HP, Tenon hospital, Centre de référence des maladies auto-inflammatoires et des amyloses d'origine inflammatoire (CEREMAIA), 20, rue de la Chine, GRC-28, Paris 75…
  • Department of Internal Medicine and Clinical Immunology France, AP-HP, Hôpital Pitié Salpetrière, Centre national de référence maladies Autoimmunes Systémiques rares, Centre national de référence maladies Autoinflammato…
  • Department of Internal Medicine, Paris Saclay University, AP-HP, Ambroise Paré Hospital, Boulogne Billancourt, France.
  • Laboratoire de Génétique des Maladies rares et autoinflammatoires, Service de Génétique moléculaire et cytogénomique, CHU Montpellier, Univ Montpellier, CeRéMAIA, Montpellier, France.

Förderung

  • Institut Imagine Institut des Maladies Génétiques

Zitieren

APA

Terré, A., Vautier, M., Kahn, J. E., Georgin-Lavialle, S., & Boursier, G. (2024). Efficacy of canakinumab for mosaic tumor necrosis factor receptor associated periodic syndrome. European Journal of Internal Medicine. https://doi.org/10.1016/j.ejim.2024.01.034

Vancouver

Terré A, Vautier M, Kahn JE, Georgin-Lavialle S, Boursier G. Efficacy of canakinumab for mosaic tumor necrosis factor receptor associated periodic syndrome. European Journal of Internal Medicine. 2024. doi:10.1016/j.ejim.2024.01.034

BibTeX
@article{Terr2024,
  author = {Terré, Alexandre and Vautier, Mathieu and Kahn, Jean-Emmanuel and Georgin-Lavialle, Sophie and Boursier, Guilaine},
  title = {Efficacy of canakinumab for mosaic tumor necrosis factor receptor associated periodic syndrome},
  journal = {European Journal of Internal Medicine},
  year = {2024},
  doi = {10.1016/j.ejim.2024.01.034}
}
Kostenlos starten →